19 August 2019
Visiongain has launched a new pharma report Pharmaceutical Contract Manufacturing Market 2019-2029: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.
The contract manufacturing sector is more mature than other sectors of the pharma outsourcing industry and has therefore grown more slowly in recent years. Additionally, external factors such as pharma industry M&A, blockbuster patent expiries and limited funding for pharma development programmes, resulting from the global economic crisis that began in 2008, have restrained growth in the market in the last five years. However, growth continues to be driven by the pharma industry’s need to cut development and manufacturing costs, with a view to improving profitability and allowing companies to focus on core competencies, such as drug discovery and development.
The lead analyst of the report commented "The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies. Many CMOs are investing in single-use technologies for biopharma manufacturing, as this provides a lower-cost solution for producing biological drugs, through continuous manufacturing processes. Microreactors will offer similar advantages in API manufacturing and CMOs will become more interested in continuous processes which are quicker, lower cost, more flexible and allow lower volume production. Other in-demand technologies will include spray drying, which will provide a cheaper alternative to lyophilisation. Spray drying also has the additional advantage of offering continuous manufacturing, Visiongain notes."
Leading companies featured in the report include Boehringer Ingelheim BioXcellence, Catalent, DPx Holdings (formerly DSM and Patheon), Evonik Degussa, Famar, Fareva, Lonza, Mylan, Teva, Vetter Pharma and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.